1.
Indian J Med Microbiol
; 39(3): 286-288, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33892973
RESUMO
Serious infections caused by MBLs with or without OXA-48-like expressing Enterobacterales remain challenging to treat. Since aztreonam is stable to MBLs, it can be combined with ceftazidime/avibactam to protect against concurrently expressed ESBLs and class C ß-lactamases in MBL pathogens. However, in the light of dose-limiting hepatotoxicity of aztreonam, short half life of avibactam, significant protein binding of aztreonam, appropriate dosing and method of administration to optimize PK/PD and toxicodynamics for this combination is being debated. Based on in-vitro PK/PD studies, simultaneous administration of 6/1.5â¯g of ceftazidime/avibactam and 8â¯g of aztreonam per day has been recently suggested.